China SXT Pharmaceuticals, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Feng Zhou
- Full Time Employees
- 56
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 178 Taidong Road North Taizhou JS People's Republic of China 225300
- IPO Date
- Jan 4, 2019
- CIK
- 0001723980
- Website
- sxtchina.com
- Similar Companies
- Business
- China SXT Pharmaceuticals, Inc. China SXT Pharmaceuticals, Inc. (SXTC) is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced TCMP, including directly-oral and after-soaking-oral varieties; fine TCMP; regular TCMP; raw medicinal materials such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang; and traditional Chinese medicine homologous supplements (TCMHS), distributed under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands to pharmaceutical companies, chain pharmacies, hospitals, and distributors. Founded in 2005 and headquartered in Taizhou, Jiangsu Province, China, it operates primarily in the domestic market within the healthcare sector's drug manufacturers - specialty and generic segment, with approximately 75 employees. Recent developments include a 1-for-8 share consolidation effective February 25, 2025, to regain Nasdaq minimum bid price compliance, which was achieved shortly thereafter; the issuance of 90 million new ordinary shares from warrant exercises between May 30 and June 2, 2025; a proposed dual-class share structure with enhanced voting rights for Class B shares discussed at a special shareholder meeting; Q4 2024 revenue of approximately $1.9 million amid partnerships with pharmaceutical firms for new drug research and development; and a leadership change with a new CEO experienced in biotech innovation.
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 37.4% in June
Cumberland Pharmaceuticals (NASDAQ:CPIX) & China SXT Pharmaceuticals (NASDAQ:SXTC) Head-To-Head Analysis
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 29.1% in February
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split
Why Is China SXT Pharmaceuticals (SXTC) Stock Up 24% Today?
Why Is China SXT Pharmaceuticals (SXTC) Stock Up 110% Today?
China SXT Pharmaceuticals (SXTC) Stock: 1-For-20 Reverse Split Goes Into Effect
Best Penny Stocks, How To Buy & Strategies for Beginners
Why Is China SXT Pharmaceuticals (SXTC) Stock Up Today?
Trading Penny Stocks? Top Stock Market News for March 29th, 2022
Best Penny Stocks To Buy? 5 Explosive Stocks Under $1 To Watch Now